Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026European Heart Journal - Cardiovascular PharmacotherapyOpen Access

Ondansetron shows a substantially stronger QT prolongation signal than olanzapine among antiemetics.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with inherited or acquired long QT syndrome and other torsadogenic risk factors, as well as general…

Design

Review

Key result

Antiemetics carry heterogeneous QT prolongation risk, with ondansetron showing a substantially stronger QT-related signal than olanzapine in disproportionality analysis (reporting OR 27.2 vs 8.7).

Authors

AMAhmed T. MoustafaODOmar DabashPPPradosh Kumar Panigrahi

Discussion

Loading...

Member takes

Overview

Heterogeneous QT signals among antiemetics may inform selection; disproportionality analysis leaves open prospective validation before practice change.

Key Points

  • Synthesize clinical and mechanistic evidence on antiemetic-induced QT prolongation to develop a three-tier, risk-stratified prescribing algorithm for patients with inherited or acquired long QT syndrome.
  • Narrative review of PubMed/MEDLINE, EMBASE, and pharmacovigilance databases (FDA Adverse Event Reporting System [FAERS], CredibleMeds) through early 2026.
  • Synthesized mechanistic studies, randomized comparisons, disproportionality analyses, and clinical consensus statements evaluating drug-induced ventricular repolarization delays.
  • Antiemetic QT liability stems primarily from IKr (hERG/KCNH2) channel blockade, displaying marked intraclass variation; a 2026 FAERS analysis revealed a higher reporting odds ratio for ondansetron compared to olanzapine (ROR 27.2 vs 8.7).
  • Butyrophenones, phenothiazines, and promethazine present substantial QT prolongation risks, whereas neurokinin-1 antagonists, palonosetron, low-risk antihistamines, anticholinergics, and 5-HT4 agonists exhibit minimal torsadogenic liability.
  • Life-threatening ventricular arrhythmias predominantly cluster in patients with baseline QTc intervals exceeding 500 ms, increases greater than 60 ms, electrolyte abnormalities, bradycardia, or concomitant torsadogenic polypharmacy.

Structured PICO

P
Population
Patients with inherited or acquired long QT syndrome (LQTS) and other torsadogenic risk factors, as well as general patients receiving antiemetics for nausea and vomiting
E
Exposure
Antiemetics (including 5-HT3 antagonists like ondansetron and palonosetron, neurokinin-1 antagonists, antihistamines, anticholinergics, 5-HT4 agonists, butyrophenones, phenothiazines, and promethazine)
O
Outcome
QT prolongation, torsades de pointes (TdP), ventricular fibrillation, and sudden cardiac deathsafety

Antiemetic-associated QT prolongation risk is highly heterogeneous, and structured risk assessment with stepwise selection of agents with minimal QT liability allows safe management of nausea and vomiting even in high-risk populations.

Cite This Study

Moustafa et al. (2026) conducted a review in Nausea and vomiting, long QT syndrome. Antiemetics was evaluated. Antiemetics carry heterogeneous QT prolongation risk, with ondansetron showing a substantially stronger QT-related signal than olanzapine in disproportionality analysis (reporting OR 27.2 vs 8.7).

synapsesocial.com/papers/6aabb8045f706d05830e7804https://doi.org/10.1093/ehjcvp/pvag077
View Full Paper
Ask AI
Bookmark
Share